Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies

MT NewswiresNov 20 08:39 ET

Express News | Ocugen Inc - to Pursue Accelerated Marketing Authorization Application for Ocu410St

ReutersNov 20 07:35 ET

Express News | Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease

ReutersNov 20 07:30 ET

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies Including Stargardt Disease

GlobeNewswireNov 20 07:30 ET

Ocugen, Inc. Reports Positive Preliminary Data From OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration

Quiver QuantitativeNov 19 07:12 ET

Ocugen Announces Preliminary Data For OCU410l; Findings Included No Drug-related Serious Adverse Events, Reduced Lesion Growth, Preservation Of Retinal Tissue, Positive Effect On The Functional Visual Measure Of Low Luminance Visual Acuity

BenzingaNov 19 07:08 ET